Differential Response of MET inhibition by Glesatinib (MGCD265) and Sitravatinib (MGCD516) in Non-small Cell Lung Cancer and Malignant Mesothelioma

被引：0
|
作者：
Mirzapoiazova, Tamara
Tan, Carol
Wang, Jiale
Mambetsariev, Isa
Mambetsariev, Bolot
Kulkarni, Prakash
Pozhitkov, Alex
Wang, Yingyu
Christensen, James
Engstrom, Lars
Salgia, Ravi
机构：
来源：
FASEB JOURNAL | 2018年 / 32卷 / 01期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
835.9
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors
    Kollmannsberger, Christian
    Hurwitz, Herbert
    Bazhenova, Lyudmila
    Cho, Byoung Chul
    Hong, David
    Park, Keunchil
    Reckamp, Karen L.
    Sharma, Sunil
    Der-Torossian, Hirak
    Christensen, James G.
    Faltaos, Demiana
    Potvin, Diane
    Tassell, Vanessa
    Chao, Richard
    Shapiro, Geoffrey, I
    TARGETED ONCOLOGY, 2023, 18 (01) : 105 - 118
  • [2] Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors
    Christian Kollmannsberger
    Herbert Hurwitz
    Lyudmila Bazhenova
    Byoung Chul Cho
    David Hong
    Keunchil Park
    Karen L. Reckamp
    Sunil Sharma
    Hirak Der-Torossian
    James G. Christensen
    Demiana Faltaos
    Diane Potvin
    Vanessa Tassell
    Richard Chao
    Geoffrey I. Shapiro
    Targeted Oncology, 2023, 18 : 105 - 118
  • [3] Evaluation of the MET/AXL Receptor Tyrosine Kinase (RTK) Inhibitor MGCD265 in a Patient with Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring AXL Amplification
    Do, Khanh T.
    Macconaill, Laura
    Dubuc, Adrian
    Chen, Isan
    Chao, Richard
    Tassell, Vanessa
    Christensen, James
    Shapiro, Geoffrey I.
    Sholl, Lynette M.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S797 - S797
  • [4] Amethyst NSCLC trial: Phase 2, parallel-arm study of receptor tyrosine kinase (RTK) inhibitor, MGCD265 in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating genetic alterations in mesenchymal-epithelial transition factor (MET)
    Bazhenova, L.
    Mehra, R.
    Nagy, T.
    Cavanna, L.
    Lee, J-S.
    Han, J-Y.
    Kim, H. K.
    Halmos, B.
    Shum, M.
    Schreeder, M.
    Rybkin, I.
    Badin, F.
    Mena, R.
    Janne, P. A.
    Christensen, J.
    Tassell, V.
    Chao, R.
    Faltaos, D.
    Kim, D-W.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] Amethyst NSCLC trial: Phase 2, parallel-arm study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) with activating genetic alterations in mesenchymal-epithelial transition factor (MET).
    Rybkin, Igor I.
    Kio, Ebenezer A.
    Masood, Ashiq
    Shum, Merrill Kingman
    Halmos, Balazs
    Blakely, Collin M.
    Eaton, Keith D.
    Sharma, Neelesh
    Nemunaitis, John J.
    Saccaro, Steven J.
    Boumber, Yanis
    Mena, Raul R.
    Mirshahidi, Hamid R.
    Janne, Pasi A.
    Christensen, James
    Chao, Richard C.
    Tassell, Vanessa Roberts
    Faltaos, Demiana
    Schreeder, Marshall T.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] MET inhibition enhances the effect of radiation in MET dysregulated non-small cell lung cancer models
    Ramesh, Shrey K.
    Javeri, Saahil N.
    Nickel, Kwangok P.
    Cifci, Ahmet
    Minne, Rachel L.
    Kimple, Randall J.
    Baschnagel, Andrew M.
    CANCER RESEARCH, 2023, 83 (07)
  • [7] About MET expression and other biomarkers in non-small cell lung cancer Response
    Sterlacci, William
    Tzankov, Alexandar
    Savic, Spasenija
    VIRCHOWS ARCHIV, 2017, 471 (05) : 687 - 688
  • [8] Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL
    Tan, Yi-Hung Carol
    Mirzapoiazova, Tamara
    Won, Brian M.
    Zhu, Li
    Srivastava, Minu K.
    Vokes, Everett E.
    Husain, Aliya N.
    Batra, Surinder K.
    Sharma, Sherven
    Salgia, Ravi
    SCIENTIFIC REPORTS, 2017, 7
  • [9] Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL
    Yi-Hung Carol Tan
    Tamara Mirzapoiazova
    Brian M. Won
    Li Zhu
    Minu K. Srivastava
    Everett E. Vokes
    Aliya N. Husain
    Surinder K. Batra
    Sherven Sharma
    Ravi Salgia
    Scientific Reports, 7
  • [10] The Persistent Promise of Combining HGF/MET and EGFR Inhibition in Non-Small Cell Lung Cancer
    Chuang, Jody C.
    Neal, Joel W.
    CANCER, 2017, 123 (15) : 2798 - 2801
12345